MedWatch

Demant CEO highlights strong performance from Diagnostics, acknowledges Communications letdown

The Danish hearing aid manufacturer’s diagnostics business area is a beacon of light among gloomy H1 financial figures, mostly coming from headset firm Epos, says CEO Søren Nielsen.

Søren Nielsen, CEO of Demant | Photo: Kenneth Lysbjerg Koustrup/ERH

Demant has had a tough second quarter, which has impacted the hearing aid manufacturer’s results for the first half of 2022 to such a degree it had to downgrade its full year guidance on Tuesday.

However, it wasn’t all bad – Demant’s business dubbed Diagnostics delivered huge growth in H1, which also meant that these results beat analysts’ expectations.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs